$6B World OTC Digestive Remedies By 1999

6 November 1995

Worldwide, the market for over-the-counter digestive remedies has been valued at $5.1 billion (at ex-manufacturers' prices) by IMS company SelfMedication International, and it is expected to grow to some $6 billion by 1999. In the 10 countries which are covered in the IMS study, accounting for 73% of the total, the 1994 market was valued at $3.7 billion and predicted to grow at a 3.4% compound annual growth rate.

The USA at 39% and Japan at 31.6% of the total are the two largest individual markets, both larger than the whole of Europe (28.4%) in 1994. By 1999, Europe will have increased to 31.8% with CAGR of 5.7%, while growth in Japan and the USA is forecast at 2.8% and 2.0% respectively. With the exception of Italy, all the European markets are forecast to increase their share of the total market, with Spain and the UK most dynamic. Prescription to OTC growth will be a major factor in stimulating these markets, but the changing profile of distribution in Europe could also play a significant role.

Country % Share Of 10 CAGR % Market Total 94-99 Belgium 1.4 5.0 France 8.8 5.5 Germany 9.1 5.8 Italy 4.8 3.6 Netherlands 1.0 6.4 Spain 2.6 8.4 UK 4.1 7.6 Total Europe 31.8 5.7 Canada 1.0 2.3 USA 36.5 2.0 Japan 30.7 2.8 Total 10 countries 100.0 3.4 Source: IMS - SelfMedication International

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight